These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 19446950)

  • 1. Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Soljanik I
    Eur Urol; 2010 Jan; 57(1):153. PubMed ID: 19446950
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Costantini E; Lazzeri M
    Eur Urol; 2010 Jan; 57(1):152-3. PubMed ID: 19446952
    [No Abstract]   [Full Text] [Related]  

  • 3. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
    Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
    Martínez-García R; Abadías M; Arañó P; Perales L; Ruíz JL; Sust M; Conejero J;
    Eur Urol; 2009 Jul; 56(1):184-90. PubMed ID: 18485575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
    May F; Bauer R
    Eur Urol; 2009 Jul; 56(1):191. PubMed ID: 18485571
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
    Lazzeri M
    Eur Urol; 2009 Jul; 56(1):191-2. PubMed ID: 18485574
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Roumeguère T
    Eur Urol; 2008 Oct; 54(4):916-7. PubMed ID: 18036722
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Kuo HC
    Eur Urol; 2008 Oct; 54(4):915-6. PubMed ID: 18036725
    [No Abstract]   [Full Text] [Related]  

  • 11. In brief: Oxytrol OTC.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):76. PubMed ID: 24662958
    [No Abstract]   [Full Text] [Related]  

  • 12. Overactive bladder: an update.
    Hashim H; Abrams P
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better management of patients with overactive bladder with antimuscarinics?
    MacDiarmid S
    Int J Clin Pract; 2008 Jan; 62(1):3-4. PubMed ID: 18173809
    [No Abstract]   [Full Text] [Related]  

  • 14. Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 May; 107(10):1612-7. PubMed ID: 21070569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial comment on: Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
    Lazzeri M
    Eur Urol; 2009 Mar; 55(3):737-8. PubMed ID: 18502027
    [No Abstract]   [Full Text] [Related]  

  • 16. Fesoterodine for the treatment of overactive bladder.
    Tzefos M; Dolder C; Olin JL
    Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin.
    Saltzstein L
    Urol Nurs; 2005 Aug; 25(4):260-2. PubMed ID: 16225342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic management of urinary incontinence, voiding dysfunction, and overactive bladder.
    Saks EK; Arya LA
    Obstet Gynecol Clin North Am; 2009 Sep; 36(3):493-507. PubMed ID: 19932412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
    Nelken RS; Ozel BZ; Leegant AR; Felix JC; Mishell DR
    Menopause; 2011 Sep; 18(9):962-6. PubMed ID: 21532512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.